

### Coronavirus-vaccine-stemirna-therapeutics/tongji-university

**S**

#### **Pityriasis rosea: case report**

A 40-year-old man developed pityriasis rosea (PR) following vaccination with coronavirus vaccine Stemirna Therapeutics/Tongji university for prophylaxis of COVID-19 infection.

The man presented with asymptomatic skin lesions over the trunk and proximal extremities of 3 weeks duration. The rash started as a single larger erythematous patch with scale on the back, disseminated with smaller lesions to the arms, thighs, chest, abdomen and flanks in a Blaschkoid distribution. He had no constitutional symptoms. He denied new medication intake or known COVID-19 exposures. However, he reported receiving the second dose of coronavirus vaccine Stemirna Therapeutics/Tongji university [mRNA COVID-19 vaccine] one week prior to the onset of the skin rash. Based on clinical presentation, he was diagnosed with PR. He elected not to do additional histopathological or blood testing.

The man was treated with triamcinolone cream for pruritus on an as-needed basis. The rash resolved 3 weeks afterwards.

Abdullah L, et al. Pityriasis rosea after mRNA COVID-19 vaccination. *International Journal of Dermatology* 60: 1150-1151, No. 9, Sep 2021. Available from: URL: <http://doi.org/10.1111/ijd.15700>

803593814